Vor Biopharma stock soars after licensing deal for autoimmune therapy

Published 26/06/2025, 14:26
© Reuters.

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock surged 85% after the company announced an exclusive licensing agreement with China’s RemeGen Co., Ltd. for telitacicept, a novel dual-target fusion protein for autoimmune diseases.

The deal grants Vor Bio global rights to develop and commercialize telitacicept outside of China, Hong Kong, Macau, and Taiwan. Under the agreement terms, Vor Bio will pay RemeGen an initial $125 million, consisting of a $45 million upfront payment and $80 million in warrants to purchase common stock. The agreement also includes potential regulatory and commercial milestones exceeding $4 billion, plus tiered royalties.

Telitacicept is already approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. The therapy works by targeting BlyS and APRIL, cytokines critical to B cell survival, thereby reducing autoreactive B cells and autoantibody production. RemeGen is currently conducting a global Phase 3 clinical trial with initial results expected in the first half of 2027.

Alongside the licensing announcement, Vor Bio revealed a leadership change, appointing Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board, effective immediately. He replaces Robert Ang, who resigned but will remain as a strategic advisor through October 2025.

"I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment," said Dr. Kress. "Targeting BAFF/APRIL signaling with telitacicept represents a significant advancement in addressing autoantibody driven diseases, which is highly differentiated from other modalities in this space."

Dr. Kress previously served as CEO of MorphoSys, where he led the development and commercialization of Monjuvi and guided the company through its acquisition by Novartis (SIX:NOVN) in 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.